Edgewise Therapeutics Inc.

26.83+1.42+5.59%Vol 322.31K1Y Perf -10.50%
Jun 16th, 2021 16:00 DELAYED
BID26.83 ASK26.93
Open25.45 Previous Close25.41
Pre-Market- After-Market-
 - -  - -%
Target Price
34.33 
Analyst Rating
— — 0.00
Potential %
27.95 
Finscreener Ranking
 —    -
Insiders Trans % 3/6/12 mo.
-/-/- 
Value Ranking
 —    -
Insiders Value % 3/6/12 mo.
-/-/- 
Growth Ranking
 —    -
Insiders Shares Cnt. % 3/6/12 mo.
-/-/- 
Income Ranking
 —    -
Market Cap1.32B 
Earnings Rating
Price Range Ratio 52W %
29.66 
Earnings Date
12th Aug 2021

Today's Price Range

25.4527.47

52W Range

21.0740.49

Summary:

Neutral

Technical Indicators: Sell
Moving Averages: Neutral
Performance
1 Week
3.55%
1 Month
-3.49%
3 Months
-
6 Months
-
1 Year
-10.50%
3 Years
-
5 Years
-
10 Years
-

TickerPriceChg.Chg.%
EWTX26.831.42005.59
AAPL130.46-1.3300-1.01
GOOG2 511.35-16.0700-0.64
MSFT259.43-1.4700-0.56
XOM60.40-1.5900-2.56
WFC41.75-1.0400-2.43
JNJ161.98-3.2400-1.96
FB329.66-6.8500-2.04
GE12.78-0.2200-1.69
JPM147.92-3.8400-2.53
Earnings HistoryEstimateReportedSurprise %
Q01 2021-0.16-0.1412.50
----
----
----
----
----
----
----
Earnings Per EndEstimateRevision %Trend
----
----
----
----
Next Report Date12th Aug 2021
Estimated EPS Next Report-0.18
Estimates Count3
EPS Growth Next 5 Years %-
Volume Overview
Volume322.31K
Shares Outstanding49.25M
Trades Count3.05K
Dollar Volume0
Avg. Volume172.61K
Avg. Weekly Volume164.96K
Avg. Monthly Volume155.84K
Avg. Quarterly Volume172.61K

Edgewise Therapeutics Inc. (NASDAQ: EWTX) stock closed at 26.39 per share at the end of the most recent trading day (a 5.59% change compared to the prior day closing price) with a volume of 724.95K shares and market capitalization of 1.32B. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 19 people. Edgewise Therapeutics Inc. CEO is Kevin Koch.

The one-year performance of Edgewise Therapeutics Inc. stock is -10.5%, while year-to-date (YTD) performance is %. EWTX stock has a five-year performance of %. Its 52-week range is between 21.07 and 40.49, which gives EWTX stock a 52-week price range ratio of 29.66%

Edgewise Therapeutics Inc. currently has a PE ratio of -5.10, a price-to-book (PB) ratio of 4.17, a price-to-sale (PS) ratio of -, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -6.67%, a ROC of -6.79% and a ROE of -6.77%. The company’s profit margin is -%, its EBITDA margin is -%, and its revenue ttm is $0.00 , which makes it $0.00 revenue per share.

Of the last four earnings reports from Edgewise Therapeutics Inc., there were 1 positive earnings surprise and 0 negative earnings surprise. The company has EPS estimate of $-0.18 for the next earnings report. Edgewise Therapeutics Inc.’s next earnings report date is 12th Aug 2021.

The consensus rating of Wall Street analysts for Edgewise Therapeutics Inc. is (), with a target price of $, which is 0.00% compared to the current price. The earnings rating for Edgewise Therapeutics Inc. stock is (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Edgewise Therapeutics Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Edgewise Therapeutics Inc. has a Neutral technical analysis rating based on Technical Indicators (ADX : 40.92, ATR14 : 2.00, CCI20 : -57.72, Chaikin Money Flow : -0.10, MACD : -0.56, Money Flow Index : 50.30, ROC : -7.07, RSI : 46.58, STOCH (14,3) : 41.08, STOCH RSI : 1.00, UO : 43.45, Williams %R : -58.92), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Edgewise Therapeutics Inc. in the last 12-months were:

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
0
0
0
Moderate Buy
0
0
0
Hold
0
0
0
Moderate Sell
0
0
0
Strong Sell
0
0
0
Summary Rating---

Edgewise Therapeutics Inc.

Edgewise Therapeutics Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development and commercialization of innovative treatments for severe, rare muscle disorders. It is developing orally bioavailable, small molecule therapies for musculoskeletal diseases.

CEO: Kevin Koch

Telephone: +1 303 735-8373

Address: 3415 Colorado Avenue, Boulder 80303, CO, US

Number of employees: 19

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

50%50%

Bearish Bullish

0%100%

Bearish Bullish

100%0%

News

Stocktwits